ChiCTR1800019782.

Trial name or title	The effect of Intense pulsed light on moderate meibomian gland dysfunction
Methods	Study design: randomised controlled trial Study grouping: parallel group Exclusions after randomisation? Not applicable Percentage of participant follow‐up: not applicable Study duration (of intervention): not reported Was a sample size calculation reported: no
Participants	Baseline characteristics IPL + MGX group Number of participants (number of eyes): 30 (not reported) Sex: not reported Age: not reported MGX (standard therapy) group Number of participants (number of eyes): 30 Sex: not reported Age: not reported Overall Number of participants (number of eyes): 60 (not reported) Sex: not reported Age: not reported Inclusion criteria: aged ≥ 18 years; SPEED score ≥ 6 points; eyelid margin obtuse or hypertrophy or new blood vessels; meibomian gland orifices obstruction, uplift or lipid suppository form; meibum quality score of a single eyelid 5–10 points; Schimer test > 5 mm Exclusion criteria: eye infection, surgery or trauma in past 6 months; eyelid closure insufficiency, entropion or ectropion, etc.; Fitzpatrick skin category 5–6; treatment before 4 weeks with a tan or tanning, tender skin treatment or have been too sensitive or allergic symptoms; pretreatment area is skin cancer or pigmentary lesions; in past month have dry eye physical therapy or point with anti‐inflammatory drugs; systemic immune‐related diseases, such as Sjogren's syndrome, Stevens‐Johnson syndrome, rheumatism, etc.; nerve lesions, such as trigeminal nerve tumours, surgery or trauma, virus damage, etc.; people with metabolic diseases such as diabetes mellitus, hypothyroidism and thyroid hyperfunction, etc. Significant pretreatment baseline differences? Not applicable Severity of dry eye: not reported
Interventions	IPL + MGX Description: 520 nm IPL + MGX Duration: not reported Co‐interventions: not reported Standard therapy only Description: MGX Duration: not reported Co‐interventions: not reported
Outcomes	Primary outcomes: SPEED score blepharoplasty score location of Marx line inflammatory factors expression in ocular surface
Starting date	Recruiting status: recruiting (as of 18 September 2019)
Contact information	Study leader: Zeng Qingyan Hankou Aier Eye Hospital, 328 Machang Road, Jianghan District, Wuhan, Hubei, China Email: zengqingyan1972@163.com Telephone: +86 13971009610
Notes	None